Preparation and application of humanized anti-spasmotoxin monoclone antibody

A monoclonal antibody, tetanus toxin technology, applied in the application, antibody, botanical equipment and methods, etc., to avoid pollution, long-acting drug concentration effect

Inactive Publication Date: 2008-07-16
龚小迪
View PDF0 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

All the methods for screening anti-tetanus toxin antibodies reported so far can only obtain a part, or even a small

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation and application of humanized anti-spasmotoxin monoclone antibody
  • Preparation and application of humanized anti-spasmotoxin monoclone antibody
  • Preparation and application of humanized anti-spasmotoxin monoclone antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0099] Example 1: Obtaining and screening human-derived plasma cells that secrete anti-tetanus toxin antibodies.

[0100] 100 ml of peripheral blood was obtained from a healthy 20-year-old male donor who had recently been immunized with tetanus vaccine. The blood donor had no history of any chronic disease, had no disease symptoms at the time of blood donation, had been immunized against tetanus 15 days before, and had not received any other vaccines in the past year. The whole blood was treated with EDTA and centrifuged through a Ficoll density gradient at 3000 rpm for half an hour. Blood leukocytes were obtained by aspirating the middle layer of Ficoll. Put the white blood cell suspension into the cell culture bottle and incubate at 37 degrees for 1 hour to remove the mononuclear cells adhering to the plastic surface. Anti-CD19 antibody-conjugated magnetic beads (Dynabeads) were mixed with washed non-adherent leukocytes (20 magnetic beads / 1×10 8cells / ml) and incubated for...

Embodiment 2

[0101] Example 2: Cloning of variable region gene fragments of human anti-tetanus toxin antibody.

[0102] First, the cells of the plasma cell clones screened in Example 1 were dissolved with a solution containing NP-40 and an RNase inhibitor at 4° C. for 10-30 minutes. Cell lysates are mixed with buffer containing reverse transcriptase. The mRNA of each clone was individually converted into a cDNA library by a reverse transcription biochemical reaction. The details are as follows: the reverse transcription reaction conditions are 65° C. for 3 minutes, slowly lower the temperature to 22° C., and keep warm for 3 minutes. Add fresh buffer containing reverse transcriptase. Incubate at 38°C for 100 minutes. Afterwards, it was incubated at 65°C to terminate the reverse transcription reaction.

[0103] Design a set of primers as shown below to clone the light and heavy chains of the antibody. VH primers include:

[0104] GGG AAT TCC CAT GGA CTG GAC CTG GA

[0105] GGG AAT TCA...

Embodiment 3

[0118] Example 3: Construction of the expression vector of human anti-tetanus toxin antibody.

[0119] figure 2 and Figure 3 is a schematic diagram of the antibody heavy chain carrier hCg1 and the antibody light chain carrier hCK. In these two vectors, we choose CMV as the promoter and EU as the enhancer. The size of the vector is about 7000bp. In both vectors, the constant region IgG of the antibody IgG heavy chain γ The cDNAs of the constant region k of 1 and the light chain have been respectively connected to the downstream of the promoter in the vector CMV. The heavy chain and light chain variable region gene fragments of the antibody cloned in Example 1 and attached to the pCR2.1 plasmid vector were excised with specific restriction enzymes, and separated and purified. The variable region genes of the heavy chain and light chain were respectively connected to two different expression vectors: the variable region gene of the light chain was connected to the antibody li...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Molecular weightaaaaaaaaaa
Login to view more

Abstract

The invention provides a human McAb to tetanus toxin, which is a human antibody comprising a variable region of the antibody. The antibody consists of or not consists of a constant region of the antibody and has the ability of neutralizing the tetanus toxin, with the variable region gene and protein sequence indicated as the sequence table 1. The antibody is characterized in that the antibody can not induce obvious allergic reaction, has higher titer and longer effect without any animal virus pollution, and can be produced in an unlimited quantity. The antibody also provides the relating biological functions, the testing methods, the manufacturing method and the application.

Description

1. Technical field [0001] The invention relates to the preparation and application of a human-derived anti-tetanus toxin monoclonal antibody; it is a divisional application with the filing date of December 30, 2003 and the patent application number of 2003101221874. 2. Background technology [0002] Tetanus, commonly known as tetanus, is a common and fatal disease caused by the infection of the tetani bacillus. Bacillus tetani widely exists in soil, dust, rust, etc., and it is easy to infect the human body with trauma, such as general trauma, trauma when women give birth to babies, etc. After a person is infected by Bacillus tetanus, the bacteria multiply in the human body and release toxins during the incubation period of about seven days. Tetanus toxin causes fatal damage to humans by destroying human nerve cells. The mortality rate is as high as 90%. Once the toxin binds to the nerve cells, it will immediately cause severe neurological symptoms, and the patient will su...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/18C12N15/13C12P21/08A61K39/395A61P31/00G01N33/53G01N33/577
Inventor 龚疆红李卓娅
Owner 龚小迪
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap